spacer
home > ict > spring 2020 > transformational real-world applications
PUBLICATIONS
International Clinical Trials

Transformational Real-World Applications



As part of wider measures to improve patient safety across the EU, the EMA and a range of other stakeholders (from national authorities, pharmaceutical industry brands, and patient advocates to life science IT and service providers) have invested considerable thought, time, and budget into preparing for the region’s implementation of the ISO identification of medicinal products (IDMP) standards over recent years. When this work finally comes to fruition, there will be much gained – not least in bringing new innovation to care and services based on the sharing of reliable, current medicinal information to any interested party internationally.

The goal of IDMP is to build a comprehensive central database of medicinal products that can be readily searched, understood, and relied upon from country to country. Substance, product, organisation, and referential (SPOR) data management services are key to enabling this. Agreed terminology, product definitions, and data formats will enable meaningful data sharing across departmental, organisational, and geographical borders, supporting a wide range of potential use cases – underpinned by a target operating model. This will assess data during the regulatory process to ensure quality and consistency, and optimise the exchange of application data between regulators and applicants.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Remco Munnik is Associate Director at Iperion, a globally-operating life science consultancy firm that is paving the way to digital healthcare and, as such, strongly committed to contributing to the actual implementation of the ISO IDMP standards.

remco.munnik@iperion.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement